MiNK Therapeutics (NASDAQ:INKT) Given New $4.00 Price Target at Robert W. Baird

MiNK Therapeutics (NASDAQ:INKT) had its target price decreased by analysts at Robert W. Baird from $8.00 to $4.00 in a note issued to investors on Friday,Benzinga reports. The firm presently has an “outperform” rating on the stock. Robert W. Baird’s price target would indicate a potential upside of 430.50% from the stock’s previous close.

Separately, HC Wainwright reissued a “buy” rating and set a $9.00 target price on shares of MiNK Therapeutics in a report on Wednesday, October 9th.

MiNK Therapeutics Price Performance

NASDAQ INKT opened at $0.75 on Friday. The company’s 50 day moving average is $0.73 and its 200-day moving average is $0.85. MiNK Therapeutics has a 12-month low of $0.57 and a 12-month high of $1.90.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in MiNK Therapeutics stock. Renaissance Technologies LLC boosted its position in shares of MiNK Therapeutics, Inc. (NASDAQ:INKT) by 21.5% in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 127,841 shares of the company’s stock after acquiring an additional 22,613 shares during the period. Renaissance Technologies LLC owned 0.37% of MiNK Therapeutics worth $121,000 as of its most recent SEC filing. 2.87% of the stock is owned by institutional investors and hedge funds.

About MiNK Therapeutics

MiNK Therapeutics, Inc, a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. Its product candidate is AGENT-797, an off-the-shelf, allogeneic for iNKT cell therapy and treatment of various myeloma diseases and solid tumours, which is in Phase 1 clinical trials.